3d Medicines (Beijing) Co., Ltd.;Jiangsu Alphamab Biopharmaceuticals Co., Ltd.
发明人:
申请号：
EP16832290.7
公开号：
EP3348571A4
申请日:
2016.08.01
申请国别(地区):
EP
年份:
2019
代理人:
摘要：
The present invention relates to the field of medical biology, and discloses a single domain antibody and derivative proteins thereof against programmed death ligand (PDL1). In particular, the present invention discloses a programmed death ligand 1 (PDL1) binding molecular and the use thereof, especially the use for treating and/or preventing or diagnosing PDL1 relevant diseases such as tumor.
